{"entity":{"id":"neu-002","kind":"drug","name":"NEU-002","aka":[],"tldr":"NEU-002 is an experimental enzyme therapy: elastase for intravenous delivery from Onchilles Pharma, in preclinical development for solid tumours.","summary":"NEU-002 is an enzyme therapy: elastase for intravenous delivery from Onchilles Pharma. The intravenous counterpart of N17350, built on the same ELANE-pathway approach and designed to eliminate tumours while mobilising an adaptive immune response. Its furthest stage is preclinical development, for solid tumours (not specified). No clinical trial naming it is registered on ClinicalTrials.gov. Company: 'continues through preclinical development'. No registered trial. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"Onchilles Pharma: onchillespharma.com","url":"https://www.onchillespharma.com/"},{"label":"Onchilles Pharma: onchillespharma.com","url":"https://www.onchillespharma.com/"}],"tags":["pipeline"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["onchilles-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"NEU-002","modality":"Enzyme therapy: elastase for intravenous delivery","mechanism":"The intravenous counterpart of N17350, built on the same ELANE-pathway approach and designed to eliminate tumours while mobilising an adaptive immune response.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/neu-002/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"onchilles-pharma","kind":"company","name":"Onchilles Pharma","route":"/companies/onchilles-pharma/"}]}}